Summit Therapeutics logged a -2.4% change during today's afternoon session, and is now trading at a price of $17.42 per share. The S&P 500 index moved 1.0%. SMMT's trading volume is 1,090,671 compared to the stock's average volume of 4,015,173.
Summit Therapeutics trades -45.57% away from its average analyst target price of $32.0 per share. The 13 analysts following the stock have set target prices ranging from $11.809112 to $42.099983, and on average have given Summit Therapeutics a rating of buy.
If you are considering an investment in SMMT, you'll want to know the following:
-
Summit Therapeutics has moved -7.1% over the last year, and the S&P 500 logged a change of 11.4%
-
Based on its trailing earnings per share of -1.25, Summit Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of -13.9 while the S&P 500 average is 29.3
-
SMMT has a forward P/E ratio of -45.8 based on its forward 12 month price to earnings (EPS) of $-0.38 per share
-
Its Price to Book (P/B) ratio is 67.52 compared to its sector average of 3.19
-
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
-
Based in Miami, the company has 159 full time employees and a market cap of $12.97 Billion.
